Jonathan Dawson – VJRegenMed

Healing diabetic ulcers with nanoclays

Simon Ng — Mon, 17 Jan 2022 18:10:25 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, gives an overview of utilizing nanoclays in treating diabetic foot ulcers. Nanoclays can concentrate proteins from the surrounding area, and administration of vascular endothelial growth factor (VEGF) in the wound area has shown to stimulate angiogenesis and thus enhance wound repair in patients with diabetes. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

The osteogenic properties of nanoclays

Simon Ng — Mon, 17 Jan 2022 18:10:23 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, discusses how the properties nanoclays can promote bone regeneration. Magnesium, lithium, and silicate ions released as a result of nanoclay degeneration have proven to stimulate osteogenic pathways in vivo, and nanoclays can modulate macrophage activity, further enhancing bone regeneration. Additional in vivo studies have demonstrated the safety of nanoclays, which do not aggregate in blood or tissue and instead are excreted via the urine. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Future applications of BMP-2

Simon Ng — Thu, 13 Jan 2022 16:36:08 +0000

Bone morphogenetic protein 2 (BMP-2) is a growth factor currently used for spinal fusion in patients. Jonathan Dawson, PhD, University of Southampton, Southampton, UK, comments on potential applications of BMP-2 beyond fusing spinal discs in the lower spine. Due to high concentrations of BMP-2 required, it is only administered in the lower spine. Dr Dawson discusses research being carried out to safely use BMP-2 in other areas of the spine and in an outpatient setting. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Clinical translation of regenerative nanoclays

Simon Ng — Mon, 10 Jan 2022 15:38:50 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, provides an overview of barriers to developing regenerative nanoclays for the clinic. Refining the manufacturing process so that the final product adheres to good manufacturing process (GMP) standards and is clinical-grade is important. As the nanoclay additionally contains bone morphogenetic protein 2 (BMP-2), classification of the product may present challenges to regulatory authorities, and varying regulatory requirements across different countries will also present potential barriers. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Regenerative nanoclays in bone regeneration

Simon Ng — Mon, 10 Jan 2022 15:38:48 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, describes the mechanism of action of regenerative nanoclays. Nanoclays have reversible gel-like properties when in water and can attract proteins with their charge. These properties enable nanoclays to be used in bone growth, as growth factors including bone morphogenetic protein 2 (BMP-2) can aggregate within the nanoclay and be delivered to a localized area, reducing the dosage needed. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).